摘要
目的探讨儿茶酚胺氧位甲基转移酶(COMT)基因Val158Met多态性与阿立哌唑治疗精神分裂症患者疗效的相关性。方法选取接受阿立哌唑治疗的精神分裂症患者80例作为治疗组,选取同期愿意充当精神疾病志愿者的健康人70例作为对照组。应用即聚合酶链式反应-限制性片段长度多态分析(PCR-RFLP)与即阳性、阴性症状评定表(PANSS)进行基因分型与精神症状评定,同时观察应用阿立哌唑治疗的临床效果。结果 2组的基因型及等位基因频率比较差异有统计学意义(P均<0.05)。经阿立哌唑治疗后,患者PANSS评分明显降低(P<0.05)。3种基因型应用阿立哌唑治疗后疗效比较差异无统计学意义(P均>0.05)。结论 COMT基因Val158Met多态性并不关联于临床症状的改善,阿立哌唑治疗精神分裂,能够有效改善患者精神状况及部分认知状况。
Objective It is to approach the correlation of COMT gene Val158Met polymorphism and clinical effect of aripi- prazole in treatment of schizophrenic patients. Methods 80 cases of schizophrenia patients received aripiprazole were selected as treatment group, 70 cases of healthy people who willing to volunteer spirit disease were selected as control group. The clini- cal data were retrospectively analyzed, as the treatment group. The genotyping were detected by Polymerase Chain Reaction re- striction fragment length polymorphism analysis （PCR -RFLP） , the symptoms were evaluated by Positive and Negative Symp- tom Scale （PANSS）. At the same time, the curative effects were observed. Results There was significant differences in the gcnotypes and allele frequency between both groups （all P 〈 0.05）. After treatment by aripiprazole, the PANSS scores were significantly reduced in treatment group （P 〈 0.05 ） , but there was no significant difference between the three genotypes after treatment by aripiprazole （ all P 〉 0.05 ）. Conclusion COMT gene Val158Met polymorphism is not associated with the im- provement of clinical symptom, aripiprazole in treatment of schizophrenia patients to mental health, can effectively improve the patient~ mental health and part of cognitive status.
出处
《现代中西医结合杂志》
CAS
2015年第6期580-582,605,共4页
Modern Journal of Integrated Traditional Chinese and Western Medicine
